BIOMAT Database Logo BIOMAT Database Logo

Further characterization of the in vitro and in vivo activity of ciprofloxacin against mycoplasmas. 1987

P M Furneri, and G Tempera, and A Chiarenza, and F Caccamo, and A M Speciale, and G Nicoletti
Institute of Microbiology, University of Catania, Italy.

The aim of this study was the evaluation of some parameters which might better characterize ciprofloxacin: the influence of inoculum, serum and medium. Resistance development, hamster protection and mycoplasmacidal concentrations were also investigated. Ciprofloxacin showed moderate antimycoplasmal activity, both in vitro and in vivo. The minimum inhibitory concentrations (MICs) for Ureaplasma urealyticum, if compared to those shown by erythromycin, are lower, but higher than those obtained with tetracyclines. Unlike the macrolides, ciprofloxacin suffers from change of inoculum size, but no single step resistance induction was reported both in ureaplasmas and mycoplasmas. If Mycoplasma pneumoniae pneumonia or genital infections due to U. urealyticum carry out gram-negative rod isolation, ciprofloxacin can be considered a valid therapeutic agent for these mixed infections.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009177 Mycoplasma pneumoniae Short filamentous organism of the genus Mycoplasma, which binds firmly to the cells of the respiratory epithelium. It is one of the etiologic agents of non-viral primary atypical pneumonia in man. Eaton Agent
D011019 Pneumonia, Mycoplasma Interstitial pneumonia caused by extensive infection of the lungs (LUNG) and BRONCHI, particularly the lower lobes of the lungs, by MYCOPLASMA PNEUMONIAE in humans. In SHEEP, it is caused by MYCOPLASMA OVIPNEUMONIAE. In CATTLE, it may be caused by MYCOPLASMA DISPAR. Mycoplasma Pneumonia,Pneumonia, Primary Atypical,Mycoplasma dispar Infection,Mycoplasma ovipneumoniae Infection,Mycoplasma pneumoniae Infection,Atypical Pneumonia, Primary,Atypical Pneumonias, Primary,Mycoplasma Pneumonias,Mycoplasma dispar Infections,Mycoplasma ovipneumoniae Infections,Mycoplasma pneumoniae Infections,Pneumonias, Mycoplasma,Pneumonias, Primary Atypical,Primary Atypical Pneumonia,Primary Atypical Pneumonias
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D003470 Culture Media Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as AGAR or GELATIN. Media, Culture
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014509 Ureaplasma A genus of gram-negative, nonmotile bacteria which are common parasitic inhabitants of the urogenital tracts of humans, cattle, dogs, and monkeys. T-Mycoplasma,Ureaplasma parvum,Ureaplasma urealyticum biovar 1

Related Publications

P M Furneri, and G Tempera, and A Chiarenza, and F Caccamo, and A M Speciale, and G Nicoletti
The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro.
August 1984, European journal of clinical microbiology,
P M Furneri, and G Tempera, and A Chiarenza, and F Caccamo, and A M Speciale, and G Nicoletti
In vitro and in vivo activity of spectinomycin against the genital mycoplasmas.
September 1974, Journal of the American Venereal Disease Association,
P M Furneri, and G Tempera, and A Chiarenza, and F Caccamo, and A M Speciale, and G Nicoletti
[In vitro activity of sparfloxacin against mycoplasmas].
May 1992, Pathologie-biologie,
P M Furneri, and G Tempera, and A Chiarenza, and F Caccamo, and A M Speciale, and G Nicoletti
In-vitro activity of ketolides against mycoplasmas.
May 1997, The Journal of antimicrobial chemotherapy,
P M Furneri, and G Tempera, and A Chiarenza, and F Caccamo, and A M Speciale, and G Nicoletti
In vitro activity of tiamulin against porcine mycoplasmas.
January 1985, Research in veterinary science,
P M Furneri, and G Tempera, and A Chiarenza, and F Caccamo, and A M Speciale, and G Nicoletti
In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates.
January 2019, Infection and drug resistance,
P M Furneri, and G Tempera, and A Chiarenza, and F Caccamo, and A M Speciale, and G Nicoletti
The in vitro and in vivo activity of ciprofloxacin.
August 1984, European journal of clinical microbiology,
P M Furneri, and G Tempera, and A Chiarenza, and F Caccamo, and A M Speciale, and G Nicoletti
In vitro activity of ciprofloxacin against mycobacteria.
June 1985, European journal of clinical microbiology,
P M Furneri, and G Tempera, and A Chiarenza, and F Caccamo, and A M Speciale, and G Nicoletti
In-vitro activity of zidovudine, zalcitabine, and didanosine against mycoplasmas.
November 1993, Lancet (London, England),
P M Furneri, and G Tempera, and A Chiarenza, and F Caccamo, and A M Speciale, and G Nicoletti
The activity of miokamycin (MOM) against Chlamydia trachomatis and mycoplasmas in vitro.
November 1983, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!